Abstract | PURPOSE: Most lung cancer patients have some resistance to and suffer from side effects of conventional chemotherapy. Thus, identification of a novel anticancer drug with better target selectivity for lung cancer treatment is urgently needed. EXPERIMENTAL DESIGN: In order to investigate whether OSU03013, a derivative of celecoxib, can be a potential drug for lung cancer treatment, we examined its cytotoxicity mechanisms by flow cytometry and phosphatidylserine staining in A549, CL1-1, and H1435 lung cancer cell lines, which are resistant to the conventional drug, cisplatin. In addition, we identified the affected proteins by proteomics and confirmed the selected proteins by Western blot analysis. We examined the interaction between OSU03013 and potential target protein by molecular modeling. RESULTS: CONCLUSIONS:
|
Authors | Yi-Hung Tan, Kung-Hsueh Lee, Topp Lin, Ying-Chieh Sun, Hsiu Mei Hsieh-Li, Hsueh-Fen Juan, Yi-Ching Wang |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 14
Issue 6
Pg. 1823-30
(Mar 15 2008)
ISSN: 1078-0432 [Print] United States |
PMID | 18347185
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- OSU03013
- Pyrazoles
- Sulfonamides
- Cyclic AMP-Dependent Protein Kinases
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Apoptosis
(drug effects)
- Carcinoma
(drug therapy, metabolism)
- Cell Line
- Cell Line, Tumor
- Cyclic AMP-Dependent Protein Kinases
(metabolism)
- Drug Evaluation, Preclinical
- Endoplasmic Reticulum
(drug effects, metabolism)
- Female
- G1 Phase
(drug effects)
- Humans
- Lung Neoplasms
(drug therapy, metabolism)
- Models, Biological
- Models, Molecular
- Proteomics
(methods)
- Pyrazoles
(pharmacology, therapeutic use)
- Sulfonamides
(pharmacology, therapeutic use)
|